Kiora Pharmaceuticals shares surge 21.80% intraday after securing up to $24M private placement and entering securities purchase agreement with Perceptive Advisors and ADAR1 Capital.

Kiora Pharmaceuticals surged 21.80% intraday, driven by two major announcements: On April 7, the company completed a private placement offering with up to $24 million in total financing, with $5 million already received and an additional $19 million available through milestone-based warrants, intended to support operations and R&D. On April 3, Kiora entered into a securities purchase agreement with Perceptive Advisors and ADAR1 Capital Management, issuing 438,471 shares of common stock at $2.543 per share, along with accompanying warrants.